It’s not a vaccine, but it’s as close as we’ve come as far as treating the symptoms of the novel coronavirus since the pandemic began. Yesterday afternoon, the FDA formally approved Gilead Sciences’ (GILD) antiviral drug remdesivir as a treatment for the coronavirus, which marks the nation’s first and only fully approved antiviral drug treatment
After good news yesterday from AstraZeneca’s (AZN) camp on the company’s seal of approval from the EU and what that could mean for the potential roll-out of its coronavirus vaccine, another big pharmaceutical name comes reveals a critical vaccine update. This past July, Moderna (MRNA) launched its 30,000-person, late-stage, clinical trial in the U.S. testing the
As the world searches for any legitimate hope of having a reliable weapon in the war against COVID-19, this weekend’s news might be as close as we’ve ever been. Yesterday, National Health Service deputy chief medical officer Jonathan Van-Tam, was quoted in a London’s Sunday Times report, saying AstraZeneca (AZN) could be rolling out its COVID-19
Heading into the winter months, it doesn’t look as promising as we would have hoped on the COVID-19 front, according to Dr. Anthony Fauci. On Thursday, 63,600 new cases in the U.S. were reported, pushing the seven-day average of daily new cases up more than 13% compared with a week ago. With cases on the
Has Pfizer won the race to find a safe COVID-19 vaccine that can help get the world back to normal? In an open letter, Pfizer (PFE) CEO Albert Bourla said the company may file for emergency use authorization with the U.S. Food and Drug Administration for its COVID-19 vaccine as early as next month: Pfizer
Vice President Joe Biden holds a commanding lead in the national polls, but some are a bit wary of counting out Trump. We all remember how the 2016 election turned out. Hillary Clinton held a large lead in mid-October, but the polls tightened into election day and Trump pulled off the upset. Though the election
In the heat of the race to bring an approved COVID-19 vaccine to millions around the world, Novavax (NVAX) is keeping its eyes on the horizon as well. Planning for a future that seems increasingly likely to include the option annual coronavirus vaccines, the biotech firm has started development on a combined influenza/COVID-19 vaccine. Back
In the heat of a race with rivals such as Pfizer (PFE), Moderna (MRNA) and AstraZeneca (AZN) to develop a safe and effective vaccine for the coronavirus, Johnson & Johnson (JNJ) provided shareholders with strong insight on how the company has held up through uncertainty. This morning, the pharmaceutical powerhouse reported third-quarter earnings which beat
Operation Warp Speed just added yet another weapon to its arsenal in the battle against COVID-19. With a front-row seat to seeing how COVID-19-positive patients respond to antibody treatments, the White House has awarded $486 million to AstraZeneca (AZN) to further develop and supply the U.S. with up to 100,000 doses of its AZD7442, COVID-19
More great news broke yesterday afternoon on the virus diagnosis front, which has sent investors running to their brokers and trading apps. Yesterday, the lab test manufacturer GenMark Diagnostics (GNMK) announced it was granted emergency use authorization by the FDA for its rapid molecular test that can distinguish between more than 20 different viruses and bacteria, including
Ok, let’s be blunt (sorry). In a year defined by quarantines, lockdowns and record food-delivery sales, one could easily the stars would have aligned to send cannabis sales sky high (sorry, again). Instead, the industry finds itself riddled with regulatory delays, slower-than-expected retail store openings, and a persistently strong black market have all weighed on
Ever since the coronavirus pandemic began taking its toll on American, Gilead Sciences (GILD) anti-viral treatment drug Remdesivir has been front and center. The drug was among the first to be used as a treatment for the novel coronavirus after it received emergency use authorization from the FDA back in May and has since been
Late last week, the news cycle was dominated by the high-profile COVID-19 diagnosis of our commander and chief. With the situation under the largest of microscopes, every update, no matter how small turned into break news, which includes news about the White House’s decision to treat president Trump using the experimental coronavirus antibody cocktail from
